Natus Medical (BABY) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Roth Capital Raises Price Target Following Natus Medical's (BABY) 3Q Results
October 22, 2015 8:20 AM EDTRoth Capital reiterated a Buy rating on Natus Medical (NASDAQ: BABY), and raised the price target to $53.00 (from $51.00), following the company's 3Q15 earnings results. BABY continues to outperform expectations, with 3Q non-GAAP operating margin of 19.9%.
Analyst Chris Lewis commented, "We remain bullish on BABY... More



